{"summary":"A highly motivated Ph.D. scientist with more than 10 years of in-depth scientific knowledge, strong technical skills, and proven leadership in oncology research and biopharmaceutical development.\n- Strong experience with the analytical (HPLC, LC-MS\/MS) and bio-analytical (immunoassay, chromogenic assay) method development, transfer, qualification, and validation for process-residuals testing at contract research organization (CRO) or in house.\n- Comprehensive experience with the process characterization and validation of process-related impurities clearance during biopharmaceutical downstream processing. \n- Strong expertise and hands-on experience in host cell protein (HCP) immunoassay development and HCP characterization by 2D-PAGE\/2D-Western blot, 2D-DIGE, and 2D-LC-MS.\n- Extensive experience in technical writing, including the authoring and reviewing of research grant proposals, CMC regulatory filings supporting documents and the IND and BLA filing documents.\n- Familiar with QbD concept for analytical method development and hands-on experience of using DoE approach for immunoassay development.\n- Experience with biosimilar drug development, especially on the analytical characterization and similarity evaluation.\n- More than 10 years of academic research experience on cancer pharmacology and cancer biology with a deep understanding of tumor microenvironment and immunotherapies targeting the immunomodulatory receptors (IMR) on T-cells.\n- Excellent problem-solving skills and leadership skills on strategic planning and project timeline management with a proven record of getting things done in a timely manner.\n- Strong team leadership skills, communication skills and interpersonal skills with a proven record of leading high performance teams.","lastName":"Wang","objectUrn":"urn:li:member:101277133","geoRegion":"Kenilworth, New Jersey, United States","fullName":"Fengqiang Wang","firstName":"Fengqiang","currentPositions":[{"companyName":"Merck","title":"Principal Scientist","tenureAtCompany":{"numYears":13,"numMonths":5},"companyUrnResolutionResult":{"employeeCountRange":"10001+","headquarters":{"geographicArea":"New Jersey","country":"United States","city":"Rahway","postalCode":"07065","line2":"P.O. Box 2000","line1":"126 E Lincoln Ave"},"website":"http:\/\/merck.us\/2J2xAUh","flagshipCompanyUrl":"https:\/\/www.linkedin.com\/company\/merck\/","industry":"Pharmaceutical Manufacturing"},"startedOn":{"month":5,"year":2020},"companyUrn":"urn:li:fs_salesCompany:1486"}],"entityUrn":"urn:li:fs_salesProfile:(ACwAAAYJXc0BPIuM9wcnpHCASsFldi9E6tNkBSE,NAME_SEARCH,XDHU)","profilePictureDisplayImage":{"artifacts":[{"width":99,"fileIdentifyingUrlPathSegment":"100_100\/0\/1685309975716?e=1723075200&v=beta&t=VyynXnYoinK68-J9ANqLIJwMAQ8xq97ewV9rkMbszdk","height":100},{"width":199,"fileIdentifyingUrlPathSegment":"200_200\/0\/1685309975717?e=1723075200&v=beta&t=HElkZO-bRArqAA8sokDfbdphtRhduoFLka5lSWH78cs","height":200},{"width":387,"fileIdentifyingUrlPathSegment":"400_400\/0\/1685309975717?e=1723075200&v=beta&t=c6pBvkvFyES_bQWrumMkej5LRcrYLgbQyPwcOEEDEII","height":387},{"width":387,"fileIdentifyingUrlPathSegment":"800_800\/0\/1685309975717?e=1723075200&v=beta&t=6RLMkD5x7qEfgsZstDqFnQFD9bYnZwnSzH0gWti46B8","height":387}],"rootUrl":"https:\/\/media.licdn.com\/dms\/image\/D4E03AQHTlhk5i-fCLA\/profile-displayphoto-shrink_"},"projects":[],"contactInfo":{},"industry":"Pharmaceutical Manufacturing","educations":[{"endedOn":{"year":2004},"degree":"Postdoc","eduId":63456298,"schoolUrn":"urn:li:fs_salesSchool:524724","school":"urn:li:fs_salesSchool:524724","fieldsOfStudy":["Cancer Biology"],"startedOn":{"year":2002}},{"endedOn":{"year":2002},"fieldsOfStudy":["Antibody Drug Conjugates for Cancer Therapy"],"degree":"Ph.D.","schoolName":"Peking Union Medical College & Chinese Academy of Medical Sciences","eduId":64474937}],"skills":[{"numOfEndorsement":5,"name":"HPLC"},{"numOfEndorsement":12,"name":"In Vitro"},{"numOfEndorsement":2,"name":"In Vivo"},{"numOfEndorsement":0,"name":"Translational Research"},{"numOfEndorsement":4,"name":"Cell Biology"},{"numOfEndorsement":0,"name":"Cell Based Assays"},{"numOfEndorsement":4,"name":"Molecular Biology"},{"numOfEndorsement":0,"name":"Immunohistochemistry"},{"numOfEndorsement":1,"name":"Transfection"},{"numOfEndorsement":2,"name":"Cell Culture"},{"numOfEndorsement":13,"name":"Biochemistry"},{"numOfEndorsement":0,"name":"RT-PCR"},{"numOfEndorsement":2,"name":"Western Blotting"},{"numOfEndorsement":3,"name":"ELISA"},{"numOfEndorsement":0,"name":"Tissue Culture"},{"numOfEndorsement":0,"name":"Cancer"},{"numOfEndorsement":12,"name":"Protein Chemistry"},{"numOfEndorsement":0,"name":"Protein Purification"},{"numOfEndorsement":4,"name":"Cell"},{"numOfEndorsement":2,"name":"Immunology"},{"numOfEndorsement":3,"name":"Protein Expression"},{"numOfEndorsement":0,"name":"qPCR"},{"numOfEndorsement":0,"name":"RNA isolation"},{"numOfEndorsement":0,"name":"SDS-PAGE"},{"numOfEndorsement":0,"name":"Molecular Cloning"},{"numOfEndorsement":0,"name":"PCR"},{"numOfEndorsement":0,"name":"DNA"},{"numOfEndorsement":0,"name":"Fluorescence Microscopy"},{"numOfEndorsement":0,"name":"Purification"},{"numOfEndorsement":1,"name":"Pharmacology"},{"numOfEndorsement":5,"name":"Life Sciences"},{"numOfEndorsement":0,"name":"Animal Models"},{"numOfEndorsement":1,"name":"Clinical Research"},{"numOfEndorsement":0,"name":"Signal Transduction"},{"numOfEndorsement":1,"name":"Oncology"},{"numOfEndorsement":4,"name":"High Throughput Screening"},{"numOfEndorsement":2,"name":"Assay Development"},{"numOfEndorsement":4,"name":"Biotechnology"},{"numOfEndorsement":0,"name":"Technology Transfer"},{"numOfEndorsement":1,"name":"Validation"},{"numOfEndorsement":3,"name":"Drug Development"},{"numOfEndorsement":0,"name":"Biopharmaceuticals"},{"numOfEndorsement":0,"name":"Biomarkers"},{"numOfEndorsement":0,"name":"Pharmaceutical Industry"},{"numOfEndorsement":0,"name":"Analytical Chemistry"},{"numOfEndorsement":2,"name":"Drug Discovery"},{"numOfEndorsement":0,"name":"Chromatography"},{"numOfEndorsement":0,"name":"Liquid Chromatography-Mass Spectrometry (LC-MS)"},{"numOfEndorsement":2,"name":"High-Performance Liquid Chromatography (HPLC)"}],"pronoun":"He\/Him","numOfConnections":1396,"patents":[],"headline":"Principal Scientist at Merck","courses":[],"certifications":[],"memberBadges":{"premium":false,"openLink":false,"jobSeeker":false},"flagshipProfileUrl":"https:\/\/www.linkedin.com\/in\/fengqiang-wang-551b0129","organizations":[],"location":"Kenilworth, New Jersey, United States","publications":[{"publishedOn":{"month":8,"day":26,"year":2015},"description":"Comprehensive characterization of S228P hinge-modified IgG4 antibodies demonstrates their stability from forming Fab-arm exchanged hybrid molecules and suitability for biotherapeutics development. ","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26308749","name":"Comprehensive Analysis of the Therapeutic IgG4 Antibody Pembrolizumab: Hinge Modification Blocks Half Molecule Exchange In Vitro and In Vivo","publisher":"J Pharm Sci. 2015 Aug 26. doi: 10.1002\/jps.24620","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAYJXc0BPIuM9wcnpHCASsFldi9E6tNkBSE,NAME_SEARCH,XDHU)"}]},{"publishedOn":{"month":9,"day":1,"year":2015},"description":"This article describes a new mix-mode chromatography method to monitor and analyze the formation of IgG4 hybrid molecules formed in vitro and in vivo due to Fab-arm exchange. ","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26091837","name":"Analysis and purification of IgG4 bispecific antibodies by a mixed-mode chromatography","publisher":"Anal Biochem. 2015 Sep 1;484:173-9. doi: 10.1016\/j.ab.2015.06.014. Epub 2015 Jun 16","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAYJXc0BPIuM9wcnpHCASsFldi9E6tNkBSE,NAME_SEARCH,XDHU)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAA1UiQIBHnDkNV6J3M6eAEPdZq9FLewnEw8,NAME_SEARCH,RZp_)"}]},{"publishedOn":{"month":6,"day":1,"year":2015},"description":"This article is a mini-review on the risks associated with host cell proteins, regulatory requirement, monitoring and control strategies during biopharmaceuticals production","url":"http:\/\/www.biopharminternational.com\/host-cell-protein-measurement-and-control","name":"Host-Cell Protein Measurement and Control","publisher":"BioPharm International","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAYJXc0BPIuM9wcnpHCASsFldi9E6tNkBSE,NAME_SEARCH,XDHU)"}]},{"publishedOn":{"month":11,"day":1,"year":2014},"description":"This study demonstrates effective \u03b2-glucans clearance in biotherapeutics produced by either Pichia pastoris or Chinese hamster ovary (CHO) cells where \u03b2-glucan are introduced during cell culture as process-related impurities.","url":"http:\/\/www.omicsonline.org\/open-access\/demonstrating-glucan-clearance-in-cho-and-yeastproduced-monoclonal-antibodies-during-downstream-purification-processes-2155-9821.1000185.pdf","name":"Demonstrating \u03b2-glucan Clearance in CHO- and Yeast-Produced Monoclonal  Antibodies during Downstream Purification Processes","publisher":"Bioprocessing & Biotechniques","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAYJXc0BPIuM9wcnpHCASsFldi9E6tNkBSE,NAME_SEARCH,XDHU)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAHMrGMBrOTfpo3fvFbQXJYlo73BNjCtbOc,NAME_SEARCH,Fq1-)"}]},{"publishedOn":{"month":5,"day":15,"year":2013},"description":"This article describes a simple LC-MS-based method coupled with post-column partial reduction to help assign disulfide bond linkage.","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23376015","name":"Disulfide bond assignment of an IgG1 monoclonal antibody by LC-MS with post-column partial reduction.","publisher":"Anal Biochem. 2013 May 15;436(2):93-100. doi: 10.1016\/j.ab.2013.01.020. Epub 2013 Jan 29","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAYJXc0BPIuM9wcnpHCASsFldi9E6tNkBSE,NAME_SEARCH,XDHU)"}]},{"publishedOn":{"month":5,"day":1,"year":2013},"description":"This article describes the approach of using glutaminyl-peptide cyclotransferase to convert the N-terminal glutamine to pyroglutamate for the N-terminal modification characterization.","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23357233","name":"Method to convert N-terminal glutamine to pyroglutamate for characterization of recombinant monoclonal antibodies","publisher":"Anal Biochem. 2013 May 1;436(1):10-2. doi: 10.1016\/j.ab.2013.01.017. Epub 2013 Jan 25.","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAYJXc0BPIuM9wcnpHCASsFldi9E6tNkBSE,NAME_SEARCH,XDHU)"}]},{"publishedOn":{"month":10,"day":15,"year":2012},"description":"This article describes the application of a rapid digestion procedure to the glycan profile comparison of different monoclonal antibodies using stable isotope labeling. ","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23036907","name":"LC-MS analysis of glycopeptides of recombinant monoclonal antibodies by a rapid digestion procedure","publisher":"J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Oct 15;907:87-93. doi: 10.1016\/j.jchromb.2012.09.004. Epub 2012 Sep 18.","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAYJXc0BPIuM9wcnpHCASsFldi9E6tNkBSE,NAME_SEARCH,XDHU)"}]},{"publishedOn":{"month":1,"day":7,"year":2014},"description":"This article shows the work we have done while I was at Mount Sinai School of Medicine in collaboration with Dr. Analisa Difeo's lab. We started with a miRNA array to screen miRNAs disregulated in epithelial ovarian cancer as compared to normal ovarian epithelium and then focused on the mechanism study of how these miRNAs, particularly miR181a, regulate ovarian cancer invasion, migration, and metastasis. ","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24394555","name":"microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition","publisher":"Nat Commun. 2014;5:2977. doi: 10.1038\/ncomms3977","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAYJXc0BPIuM9wcnpHCASsFldi9E6tNkBSE,NAME_SEARCH,XDHU)"}]},{"publishedOn":{"month":2,"year":2004},"description":"This publication is based on part of the work I did during my graduate school study. ","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15382678","name":"Antitumor effects of the molecule-downsized immunoconjugate composed of lidamycin and Fab' fragment of monoclonal antibody directed against type IV collagenase","publisher":"Sci China C Life Sci. 2004 Feb;47(1):66-73.","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAYJXc0BPIuM9wcnpHCASsFldi9E6tNkBSE,NAME_SEARCH,XDHU)"}]},{"publishedOn":{"month":10,"day":30,"year":2013},"description":"In this article, we described the development of a more sensitive chemiluminescent detection based ELISA method for host cell protein detection and quantification, which demonstrated superiority over colorimetric method in assay performance.","url":"http:\/\/www.omicsonline.org\/the-comparison-of-chemiluminescent-and-colorimetricdetection-based-elisa-for-chinese-hamster-ovary-host-cell-proteins-quantification-in-biotherapeutics.2155-9821.1000136.php?aid=19810","name":"The Comparison of Chemiluminescent- and Colorimetric-detection Based ELISA for Chinese Hamster Ovary Host Cell Proteins Quantification in Biotherapeutics","publisher":"Journal of Bioprocessing & Biotechniques","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAYJXc0BPIuM9wcnpHCASsFldi9E6tNkBSE,NAME_SEARCH,XDHU)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAA1UiQIBHnDkNV6J3M6eAEPdZq9FLewnEw8,NAME_SEARCH,RZp_)"}]},{"publishedOn":{"month":2,"day":19,"year":2014},"description":"This article describes the development of a fully automated microfluidic assay using the Gyrolab platform host cell protein quantification in comparison with microtiter plate-based ELISA method.","url":"http:\/\/www.future-science.com\/doi\/abs\/10.4155\/pbp.14.12","name":"A microfluidic approach to high throughput quantification of host cell protein impurities for bioprocess development","publisher":"Pharmaceutical Bioprocessing","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAYJXc0BPIuM9wcnpHCASsFldi9E6tNkBSE,NAME_SEARCH,XDHU)"}]},{"publishedOn":{"month":6,"day":1,"year":2011},"description":"This article describes a new method to quantitatively detect and measure cytoskeleton stress fibers formed within ovarian cancer cells upon LPA stimulation.","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21980615","name":"Recognition of linear stress fibers based on Hough transform","publisher":"Anal Quant Cytol Histol. 2011 Jun;33(3):121-31.","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAYJXc0BPIuM9wcnpHCASsFldi9E6tNkBSE,NAME_SEARCH,XDHU)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAASy8gcBKWI6T4lwGlHwOJXL72wzh8nakIY,NAME_SEARCH,z3lj)"}]},{"publishedOn":{"month":10,"day":1,"year":2011},"description":"This is a mechanism study on the cell signaling pathways that mediate LPA-induced epithelial ovarian cancer invasion.","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21782227","name":"The NF-\u03baB pathway mediates lysophosphatidic acid (LPA)-induced VEGF signaling and cell invasion in epithelial ovarian cancer (EOC).","publisher":"Gynecol Oncol. 2011 Oct;123(1):129-37. doi: 10.1016\/j.ygyno.2011.06.006. Epub 2011 Jul 22.","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAYJXc0BPIuM9wcnpHCASsFldi9E6tNkBSE,NAME_SEARCH,XDHU)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAASy8gcBKWI6T4lwGlHwOJXL72wzh8nakIY,NAME_SEARCH,z3lj)"}]},{"publishedOn":{"month":2,"day":1,"year":2011},"description":"Our study indicates that MMP-1-PAR1 axis is involved in EOC invasion and at least partially mediates LPA-induced EOC invasion. ","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21093894","name":"MMP-1-PAR1 axis mediates LPA-induced epithelial ovarian cancer (EOC) invasion.","publisher":"Gynecol Oncol. 2011 Feb;120(2):247-55. doi: 10.1016\/j.ygyno.2010.10.032. Epub 2010 Nov 20.","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAYJXc0BPIuM9wcnpHCASsFldi9E6tNkBSE,NAME_SEARCH,XDHU)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAASy8gcBKWI6T4lwGlHwOJXL72wzh8nakIY,NAME_SEARCH,z3lj)"}]},{"publishedOn":{"month":6,"year":2010},"description":"Invited review of expert opinions on the early detection of ovarian cancer.","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20550476","name":"The dire need to develop a clinically validated screening method for the detection of early-stage ovarian cancer.","publisher":"Biomark Med. 2010 Jun;4(3):437-9. doi: 10.2217\/bmm.10.54.","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAYJXc0BPIuM9wcnpHCASsFldi9E6tNkBSE,NAME_SEARCH,XDHU)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAASy8gcBKWI6T4lwGlHwOJXL72wzh8nakIY,NAME_SEARCH,z3lj)"}]},{"publishedOn":{"month":5,"day":1,"year":2010},"description":"Invited review on the most recent developments in EOC early detection and targeted therapy, as well as new technologies for the discovery of novel biomarkers.","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20372062","name":"Biomarkers for ovarian cancer detection and therapy","publisher":"Cancer Biol Ther. 2010 May 1;9(9):668-77. Epub 2010 May 24.","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAYJXc0BPIuM9wcnpHCASsFldi9E6tNkBSE,NAME_SEARCH,XDHU)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAASy8gcBKWI6T4lwGlHwOJXL72wzh8nakIY,NAME_SEARCH,z3lj)"}]},{"publishedOn":{"month":2,"day":1,"year":2010},"description":"Invited review on the new frontiers for ovarian cancer early detection. In this article, we proposed that the use of proteomic-based biomarker discovery and contrast-enhanced ultrasound may serve as a promising combination to help accurately identify early-stage epithelial ovarian cancer to improve women's health care.","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20093595","name":"New frontiers for ovarian cancer risk evaluation: proteomics and contrast-enhanced ultrasound.","publisher":"AJR Am J Roentgenol. 2010 Feb;194(2):349-54. doi: 10.2214\/AJR.09.3763.","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAYJXc0BPIuM9wcnpHCASsFldi9E6tNkBSE,NAME_SEARCH,XDHU)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAASy8gcBKWI6T4lwGlHwOJXL72wzh8nakIY,NAME_SEARCH,z3lj)"}]},{"name":"Lysophosphatidic acid (LPA) effects on endometrial carcinoma in vitro proliferation, invasion, and matrix metalloproteinase activity","publishedOn":{"month":4,"day":1,"year":2010},"publisher":"Gynecol Oncol. 2010 Apr;117(1):88-95. doi: 10.1016\/j.ygyno.2009.12.012. Epub 2010 Jan 6.","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20056268","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAYJXc0BPIuM9wcnpHCASsFldi9E6tNkBSE,NAME_SEARCH,XDHU)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAASy8gcBKWI6T4lwGlHwOJXL72wzh8nakIY,NAME_SEARCH,z3lj)"}]},{"publishedOn":{"month":12,"day":1,"year":2009},"description":"Invited review on the roles that LPA play in ovarian cancer development and progression.","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20001802","name":"Roles of LPA in ovarian cancer development and progression","publisher":"Future Oncol. 2009 Dec;5(10):1659-73. doi: 10.2217\/fon.09.120","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABIRz6EBB4pzpmObdTc-lsaxeqRKo95fOqw,NAME_SEARCH,vubb)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAYJXc0BPIuM9wcnpHCASsFldi9E6tNkBSE,NAME_SEARCH,XDHU)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAASy8gcBKWI6T4lwGlHwOJXL72wzh8nakIY,NAME_SEARCH,z3lj)"}]},{"name":"VEGFR-2 silencing by small interference RNA (siRNA) suppresses LPA-induced epithelial ovarian cancer (EOC) invasion.","publisher":"Gynecol Oncol. 2009 Dec;115(3):414-23. doi: 10.1016\/j.ygyno.2009.08.019. Epub 2009 Sep 18","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19765808","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAYJXc0BPIuM9wcnpHCASsFldi9E6tNkBSE,NAME_SEARCH,XDHU)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAUUYbEB1-c4xD59iCz_d3ofG3Z626b_LsQ,NAME_SEARCH,XeD-)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAABIRz6EBB4pzpmObdTc-lsaxeqRKo95fOqw,NAME_SEARCH,vubb)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAASy8gcBKWI6T4lwGlHwOJXL72wzh8nakIY,NAME_SEARCH,z3lj)"}]},{"name":"LPA receptor 2 mediates LPA-induced endometrial cancer invasion","publishedOn":{"month":1,"day":3,"year":2009},"publisher":"Gynecol Oncol. 2009 Jan;112(1):215-23. doi: 10.1016\/j.ygyno.2008.09.019. Epub 2008 Nov 18","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19019417","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAYJXc0BPIuM9wcnpHCASsFldi9E6tNkBSE,NAME_SEARCH,XDHU)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAASy8gcBKWI6T4lwGlHwOJXL72wzh8nakIY,NAME_SEARCH,z3lj)"}]},{"name":"Lysophosphatidic acid (LPA) promotes E-cadherin ectodomain shedding and OVCA429 cell invasion in an uPA-dependent manner","publishedOn":{"month":2,"day":28,"year":2008},"publisher":"Gynecol Oncol. 2008 Feb;108(2):361-9","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18073130","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAuFWSkBBGvDhC2zhrFcILC17qcqjF-IaFU,NAME_SEARCH,5uBG)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAYJXc0BPIuM9wcnpHCASsFldi9E6tNkBSE,NAME_SEARCH,XDHU)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAASy8gcBKWI6T4lwGlHwOJXL72wzh8nakIY,NAME_SEARCH,z3lj)"}]},{"name":"Inhibition of matrilysin expression by antisense or RNA interference decreases lysophosphatidic acid-induced epithelial ovarian cancer invasion","publishedOn":{"month":11,"day":10,"year":2006},"publisher":"Mol Cancer Res. 2006 Nov;4(11):831-41.","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17114341","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAYJXc0BPIuM9wcnpHCASsFldi9E6tNkBSE,NAME_SEARCH,XDHU)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAASy8gcBKWI6T4lwGlHwOJXL72wzh8nakIY,NAME_SEARCH,z3lj)"}]},{"name":"S1P regulation of ovarian carcinoma invasiveness","publishedOn":{"month":12,"year":2006},"publisher":"Gynecol Oncol. 2006 Dec;103(3):952-9. Epub 2006 Sep 7.","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16956652","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAYJXc0BPIuM9wcnpHCASsFldi9E6tNkBSE,NAME_SEARCH,XDHU)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAASy8gcBKWI6T4lwGlHwOJXL72wzh8nakIY,NAME_SEARCH,z3lj)"}]},{"name":"Vascular endothelial growth factor-regulated ovarian cancer invasion and migration involves expression and activation of matrix metalloproteinases","publishedOn":{"month":2,"year":2006},"publisher":"Int J Cancer. 2006 Feb 15;118(4):879-88","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16152587","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAYJXc0BPIuM9wcnpHCASsFldi9E6tNkBSE,NAME_SEARCH,XDHU)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAF9KycBU7thVlZ61kMmIa6x4XK4q1gUKSg,NAME_SEARCH,u0f6)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAASy8gcBKWI6T4lwGlHwOJXL72wzh8nakIY,NAME_SEARCH,z3lj)"}]},{"name":"Antitumor activity of anti-type IV collagenase monoclonal antibody and its lidamycin conjugate against colon carcinoma.","publishedOn":{"month":8,"day":7,"year":2005},"publisher":"World J Gastroenterol. 2005 Aug 7;11(29):4478-83.","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16052675","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAmMR6wBPINPiKML55BJioQUl7MNelhchCg,NAME_SEARCH,nzmA)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAYJXc0BPIuM9wcnpHCASsFldi9E6tNkBSE,NAME_SEARCH,XDHU)"}]},{"name":"LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2).","publishedOn":{"month":6,"year":2005},"publisher":"Gynecol Oncol. 2005 Jun;97(3):870-8.","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15919106","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAF9KycBU7thVlZ61kMmIa6x4XK4q1gUKSg,NAME_SEARCH,u0f6)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAYJXc0BPIuM9wcnpHCASsFldi9E6tNkBSE,NAME_SEARCH,XDHU)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAHS9xEBi_4SAfVmBaj8Rw_3DrzQ9V24O9I,NAME_SEARCH,mKSg)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAASy8gcBKWI6T4lwGlHwOJXL72wzh8nakIY,NAME_SEARCH,z3lj)"}]},{"name":"Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase.","publishedOn":{"month":3,"day":10,"year":2005},"publisher":"Int J Cancer. 2005 Mar 10;114(1):19-31.","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15523695","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAYJXc0BPIuM9wcnpHCASsFldi9E6tNkBSE,NAME_SEARCH,XDHU)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAF9KycBU7thVlZ61kMmIa6x4XK4q1gUKSg,NAME_SEARCH,u0f6)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAASy8gcBKWI6T4lwGlHwOJXL72wzh8nakIY,NAME_SEARCH,z3lj)"}]},{"name":"Lysophosphatidic acid enhances epithelial ovarian carcinoma invasion through the increased expression of interleukin-8.","publishedOn":{"month":11,"year":2004},"publisher":"Gynecol Oncol. 2004 Nov;95(2):314-22.","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15491751","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAF9KycBU7thVlZ61kMmIa6x4XK4q1gUKSg,NAME_SEARCH,u0f6)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAHS9xEBi_4SAfVmBaj8Rw_3DrzQ9V24O9I,NAME_SEARCH,mKSg)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAYJXc0BPIuM9wcnpHCASsFldi9E6tNkBSE,NAME_SEARCH,XDHU)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAASy8gcBKWI6T4lwGlHwOJXL72wzh8nakIY,NAME_SEARCH,z3lj)"}]},{"publishedOn":{"year":2009},"description":"This is one of the book chapters from Ovarian Cancer 2nd edition edited by Drs. M Sharon Stack and David A. Fishman","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19763441","name":"Lysophosphatidic acid and invasion.","publisher":"Cancer Treat Res. 2009;149:269-96. doi: 10.1007\/978-0-387-98094-2_13","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAYJXc0BPIuM9wcnpHCASsFldi9E6tNkBSE,NAME_SEARCH,XDHU)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAASy8gcBKWI6T4lwGlHwOJXL72wzh8nakIY,NAME_SEARCH,z3lj)"}]},{"publishedOn":{"month":2,"year":2007},"description":"A collaboration between Dr. Fishman's Lab and Professor Zankl's lab on the cause of Torg syndrome and MMP-2.","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17059372","name":"Torg syndrome is caused by inactivating mutations in MMP2 and is allelic to NAO and Winchester syndrome","publisher":"J Bone Miner Res. 2007 Feb;22(2):329-33.","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAoWeYsBobgl8HaUvKat7hIwS_MhgiGfUpk,NAME_SEARCH,vF7D)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAYJXc0BPIuM9wcnpHCASsFldi9E6tNkBSE,NAME_SEARCH,XDHU)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAASy8gcBKWI6T4lwGlHwOJXL72wzh8nakIY,NAME_SEARCH,z3lj)"}]},{"name":"Matrilysin over-expression in MCF-7 cells enhances cellular invasiveness and pro-gelatinase activation","publishedOn":{"month":5,"day":18,"year":2005},"publisher":"Cancer Lett. 2006 May 18;236(2):292-301. Epub 2005 Jul 12.","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16019136","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAYJXc0BPIuM9wcnpHCASsFldi9E6tNkBSE,NAME_SEARCH,XDHU)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAASy8gcBKWI6T4lwGlHwOJXL72wzh8nakIY,NAME_SEARCH,z3lj)"}]},{"publishedOn":{"month":7,"year":2003},"description":"Ph.D. thesis work on the anti-tumor effects of antibody-drug conjugate in vitro and in vivo.","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/14515796","name":"Antitumor effects of the immunoconjugate composed of lidamycin and monoclonal antibody 3G11","publisher":"Yao Xue Xue Bao. 2003 Jul;38(7):515-9","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAYJXc0BPIuM9wcnpHCASsFldi9E6tNkBSE,NAME_SEARCH,XDHU)"}]},{"name":"A cytotoxic diterpenoid and antifungal phenolic compounds from Frullania muscicola Steph","publishedOn":{"month":6,"year":2002},"publisher":"J Asian Nat Prod Res. 2002 Jun;4(2):87-94","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12067164","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAYJXc0BPIuM9wcnpHCASsFldi9E6tNkBSE,NAME_SEARCH,XDHU)"}]},{"name":"A Kinase-cGAS cascade to synthesize a therapeutic STINg activator","publishedOn":{"month":3,"day":16,"year":2022},"publisher":"Nature","url":"https:\/\/www.nature.com\/articles\/s41586-022-04422-9","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAYJXc0BPIuM9wcnpHCASsFldi9E6tNkBSE,NAME_SEARCH,XDHU)"}]},{"name":"Holistic analytical characterization and risk assessment of residual host cell protein impurities in an active pharmaceutical ingredient synthesized by biocatalysts","publishedOn":{"month":4,"day":19,"year":2022},"publisher":"Biotechnol Bioeng","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/35437754\/","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAYJXc0BPIuM9wcnpHCASsFldi9E6tNkBSE,NAME_SEARCH,XDHU)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAg4KsABg7anGLzo-TgLilzWdE3Bk069pDE,NAME_SEARCH,-8ZD)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAABF8lOsBf_0MFAhO7brLcQq0rtZJlwHZ-7I,NAME_SEARCH,-4Ce)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAABWX57QB6xqTNELSMHULFmyzEdZeiAAQ1e0,NAME_SEARCH,REEg)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAAZYUkByFJJznOVdz53J2Ssn33udBlJjSg,NAME_SEARCH,tF9d)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAALLWvoB3UG67DpvW-d27fgLH_-VELWWI3E,NAME_SEARCH,Mwvg)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAD0uoQB9k-2noEgErjtA8djogxYgGQN_3k,NAME_SEARCH,75sA)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAHMrGMBrOTfpo3fvFbQXJYlo73BNjCtbOc,NAME_SEARCH,Fq1-)"}]}],"positions":null,"posts":[{"createdAt":1716254040000,"insightId":"9a40bd28-a195-467f-8d9d-fee0c0cdac42","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7197786348324274176,7198491272251080704)","threadUrn":"urn:li:ugcPost:7197786348324274176","reactionsCount":0,"commentsCount":0,"canComment":true},"commentary":{"attributes":[{"start":0,"length":10,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:140453144"}}}],"text":"Ying Zhang Yes, it was great Xin Wang and Ned was there so at least the first part of risk assessment framework was represented."},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7197786348324274176"}}},{"createdAt":1716246420000,"insightId":"9ff5b5a2-fa4d-4f1f-80f9-177ca5e5af45","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7197786348324274176,7198459441262772226)","threadUrn":"urn:li:ugcPost:7197786348324274176","reactionsCount":0,"commentsCount":0,"canComment":true},"commentary":{"attributes":[{"start":0,"length":23,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:7837066"}}}],"text":"Christina Zuch de Zafra It would have been even better if you were there. I am sure you would be interested in how they did risk assessment for MCP-1 before IMPD."},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7197786348324274176"}}},{"createdAt":1716246180000,"insightId":"bc943277-dc78-444a-b354-f2b17b40d2aa","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7197786348324274176,7198458232397344769)","threadUrn":"urn:li:ugcPost:7197786348324274176","reactionsCount":0,"commentsCount":0,"canComment":true},"commentary":{"attributes":[{"start":0,"length":11,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:4502478"}}}],"text":"Kim HuynhBa Thanks Kim."},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7197786348324274176"}}},{"createdAt":1716246000000,"insightId":"c4c90525-8b46-4639-baab-c8a9e78f2b25","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7197786348324274176,7198457604124098560)","threadUrn":"urn:li:ugcPost:7197786348324274176","reactionsCount":0,"commentsCount":0,"canComment":true},"commentary":{"attributes":[{"start":0,"length":14,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:138171547"}}}],"text":"Trish Connolly Yes, it\u2019s great meeting other BioPhorum members as well. Wished we could have more time to socialize. And forgive me for using the BioPhorum team photo without asking for permission first."},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7197786348324274176"}}},{"createdAt":1716245640000,"insightId":"f1f0058e-36c8-4958-a560-76a0014a0821","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7197786348324274176,7198456140559450114)","threadUrn":"urn:li:ugcPost:7197786348324274176","reactionsCount":0,"commentsCount":0,"canComment":true},"commentary":{"attributes":[{"start":0,"length":7,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:133608369"}}}],"text":"Feny G. It would be great to meet again at BEBPA sometime in the future."},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7197786348324274176"}}},{"createdAt":1716090000000,"insightId":"a43b70a8-502c-48b5-b196-3e34f7cfe7d8","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7197786348324274176,7197803345330225152)","threadUrn":"urn:li:ugcPost:7197786348324274176","reactionsCount":1,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"Glad to hear from you, Mimi. It has been a while!"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7197786348324274176"}}},{"createdAt":1715974620000,"insightId":"23c62bbe-c85a-485c-9a61-c2ca4f67e47a","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7196501158771781632,7197319342621892608)","threadUrn":"urn:li:ugcPost:7196501158771781632","reactionsCount":0,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"What a great three-days at BEBPA HCP conference with this special celebration! Thank you Laureen for starting such a great conference!"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7196501158771781632"}}},{"createdAt":1715967960000,"insightId":"68760b39-f276-4298-af0f-68b9daca8b7b","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7197242719461679104,7197291385492832256)","threadUrn":"urn:li:ugcPost:7197242719461679104","reactionsCount":1,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"Congratulations and welcome back to Merck!"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7197242719461679104"}}},{"createdAt":1710465420000,"insightId":"1aee934e-7721-4567-afcd-2cc2c796b747","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7170416983497236480,7174211956361363457)","threadUrn":"urn:li:ugcPost:7170416983497236480","reactionsCount":1,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"Congrats Feny"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7170416983497236480"}}}]}